Financials data is unavailable for this security.
View more
Year on year Zhongzhi Pharmaceutical Holdings Ltd grew revenues 12.26% from 1.83bn to 2.05bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 53.00% net income growth from 106.39m to 162.78m.
Gross margin | 57.55% |
---|---|
Net profit margin | 5.49% |
Operating margin | 7.50% |
Return on assets | 5.99% |
---|---|
Return on equity | 10.23% |
Return on investment | 9.17% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Zhongzhi Pharmaceutical Holdings Ltd fell by 256.64m. However, the company earned 101.50m from its operations for a Cash Flow Margin of 4.95%. In addition the company used 202.76m on investing activities and also paid 154.62m in financing cash flows.
Cash flow per share | 0.2486 |
---|---|
Price/Cash flow per share | 3.90 |
Book value per share | 1.41 |
---|---|
Tangible book value per share | 1.39 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.40 |
---|---|
Quick ratio | 0.9033 |
Total debt/total equity | 0.1795 |
---|---|
Total debt/total capital | 0.1516 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 53.01%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 0.91% |
---|---|
Div growth rate (5 year) | 3.22% |
Payout ratio (TTM) | 63.83% |
EPS growth(5 years) | 13.48 |
---|---|
EPS (TTM) vs TTM 1 year ago | -32.22 |
More ▼